Whitehawk Therapeutics (WHWK) executive exercises 366K RSUs, receives 250K-share option grant

Q: What equity awards did Bryan Ball report on this Form 4 for WHWK?

Bryan Ball reported the exercise of 366,532 restricted stock units into common shares and the grant of a stock option covering 250,058 shares . Both transactions relate to compensation , not open-market buying or selling of Whitehawk Therapeutics stock.

Q: What are the key terms of Bryan Ball’s new stock option at Whitehawk Therapeutics (WHWK)?

Bryan Ball received a stock option for 250,058 shares of common stock at an exercise price of $3.54 per share , expiring on April 1, 2036 . The option vests over four years, subject to continued service with Whitehawk Therapeutics.

Q: How do Bryan Ball’s restricted stock units (RSUs) in WHWK vest?

Each RSU represents a right to receive one common share. 100% of the RSUs vest on the one-year anniversary of the April 1, 2025 vesting commencement date, provided Bryan Ball continues as a Service Provider under the company’s 2021 Equity Incentive Plan.

Q: How does the new WHWK stock option for Bryan Ball vest over time?

The stock option vests 25% on the one-year anniversary of the April 1, 2026 vesting commencement date, then 1/48th each month thereafter. Full vesting occurs by the four-year anniversary, assuming continued service with Whitehawk Therapeutics.

Q: Were Bryan Ball’s WHWK transactions open-market buys or sells?

The Form 4 shows no open-market buys or sells . Instead, Bryan Ball exercised restricted stock units into common shares and received a new stock option grant . These are compensation-related equity events , not discretionary market trades in Whitehawk Therapeutics stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Whitehawk Therapeutics, Inc. executive Bryan Ball reported compensation-related equity activity. He exercised 366,532 restricted stock units, receiving the same number of common shares at a price of $0.00 per share. Following this RSU conversion, he directly held 572,551 shares of common stock.

Ball was also granted a new stock option for 250,058 shares of common stock with an exercise price of $3.54 per share, expiring on April 1, 2036. According to the footnotes, RSUs vest 100% one year after the April 1, 2025 vesting commencement date, and the option vests over four years starting April 1, 2026, assuming continued service.

Insider Trade Summary

366,532 shares exercised/converted

Mixed 3 txns

Insider BALL BRYAN

Role See remarks

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	366,532	$0.00	--
Grant/Award	Stock Option (right to buy)	250,058	$0.00	--
Exercise	Common Stock	366,532	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Stock Option (right to buy) — 250,058 shares (Direct); Common Stock — 572,551 shares (Direct)

Footnotes (1)

Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2026.

Key Figures

RSUs exercised: 366,532 units/shares Post-transaction common shares: 572,551 shares New stock option grant size: 250,058 shares +4 more

7 metrics

RSUs exercised 366,532 units/shares RSUs converted into common stock at $0.00 per share on April 1, 2026

Post-transaction common shares 572,551 shares Direct common stock holdings after RSU exercise

New stock option grant size 250,058 shares Stock option covering common stock granted as equity compensation

Option exercise price $3.54 per share Strike price for 250,058-share stock option

Option expiration date April 1, 2036 Expiration of Bryan Ball’s new stock option

RSU vesting cliff 100% after 1 year All RSUs vest one year after April 1, 2025, with continued service

Option vesting schedule 25% at 1 year; then monthly Option vests 25% after one year from April 1, 2026, then 1/48th monthly

Key Terms

Restricted Stock Units, Stock Option (right to buy), Vesting Commencement Date, Service Provider, +1 more

5 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (right to buy) financial

"security_title": "Stock Option (right to buy)""

Vesting Commencement Date financial

""Vesting Commencement Date" shall mean April 1, 2025."

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

Service Provider financial

"Subject to the Reporting Person continuing to be a Service Provider"

2021 Equity Incentive Plan financial

"as defined in the Issuer's 2021 Equity Incentive Plan"

Form 4 Insider Transactions: What Each Field Means →

04/03/2026 - 06:20 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BALL BRYAN

(Last)

(First)

(Middle)

C/O WHITEHAWK THERAPEUTICS, INC.

2 HEADQUARTERS PLAZA, EAST BUILDING, 11T

(Street)

MORRISTOWN

NEW JERSEY

07960

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Whitehawk Therapeutics, Inc. [ WHWK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/01/2026		M		366,532	A	⁽¹⁾	572,551	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	04/01/2026		M			366,532	⁽²⁾	⁽²⁾	Common Stock	366,532	$0	0	D
Stock Option (right to buy)	$3.54	04/01/2026		A		250,058		⁽³⁾	04/01/2036	Common Stock	250,058	$0	250,058	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.

2. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025.

3. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2026.

Remarks:

Chief Technical Operations Officer and SVP, Manufacturing Operations

	/s/ Stephen Rodin, as Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Bryan Ball report on this Form 4 for WHWK?

Bryan Ball reported the exercise of 366,532 restricted stock units into common shares and the grant of a stock option covering 250,058 shares. Both transactions relate to compensation, not open-market buying or selling of Whitehawk Therapeutics stock.

How many Whitehawk Therapeutics (WHWK) shares does Bryan Ball hold after these transactions?

After exercising RSUs into common stock, Bryan Ball directly held 572,551 shares of Whitehawk Therapeutics common stock. This figure reflects his updated ownership as reported following the April 1, 2026 equity compensation transactions disclosed in the Form 4 filing.

What are the key terms of Bryan Ball’s new stock option at Whitehawk Therapeutics (WHWK)?

Bryan Ball received a stock option for 250,058 shares of common stock at an exercise price of $3.54 per share, expiring on April 1, 2036. The option vests over four years, subject to continued service with Whitehawk Therapeutics.

How do Bryan Ball’s restricted stock units (RSUs) in WHWK vest?

Each RSU represents a right to receive one common share. 100% of the RSUs vest on the one-year anniversary of the April 1, 2025 vesting commencement date, provided Bryan Ball continues as a Service Provider under the company’s 2021 Equity Incentive Plan.

How does the new WHWK stock option for Bryan Ball vest over time?

The stock option vests 25% on the one-year anniversary of the April 1, 2026 vesting commencement date, then 1/48th each month thereafter. Full vesting occurs by the four-year anniversary, assuming continued service with Whitehawk Therapeutics.

Were Bryan Ball’s WHWK transactions open-market buys or sells?

The Form 4 shows no open-market buys or sells. Instead, Bryan Ball exercised restricted stock units into common shares and received a new stock option grant. These are compensation-related equity events, not discretionary market trades in Whitehawk Therapeutics stock.